Decrease of Let-7f in Low-Dose metronomic paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer

International Journal of Biological Sciences

Volumn 11, Issue 1, 2015, Pages 48-58

  Tao, Wei Yang ^a   Liang, Xiao Shuan ^a   Liu, Yang ^a   Wang, Chun Yang ^a,b   Pang, D ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Let 7f; Low dose metronomic paclitaxel therapy; Thrombospondin 1

Indexed keywords

ANTINEOPLASTIC AGENT; LUCIFERASE; MICRORNA; MIRNLET7 MICRORNA, MOUSE; PACLITAXEL; PRIMER DNA; THROMBOSPONDIN 1; THROMBOSPONDIN-1, MOUSE;

ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; MICROARRAY ANALYSIS; MOUSE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; BREAST NEOPLASMS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; MICRORNAS; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; THROMBOSPONDIN 1;

EID: 84912142413     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.9969     Document Type: Article

References (31)

1. Ueda S, Kuji I, Shigekawa T, Takeuchi H, Sano H, Hirokawa E, et al. Optical Imaging for Monitoring Tumor Oxygenation Response after Initiation of Single-Agent Bevacizumab followed by Cytotoxic Chemotherapy in Breast Cancer Patients. PLoS One. 9: e98715. doi:10.1371/journal.pone.0098715PONE-D-13-48502
2. Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, et al. Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. doi:10.1007/s00280-014-2481-1.
3. Gonzalez-Martin A, Sanchez-Lorenzo L, Bratos R, Marquez R, Chiva L. First-line and maintenance therapy for ovarian cancer: current status and future directions. Drugs. 2014;74: 879-89. doi:10.1007/s40265-014-0221-9.
4. Misiukiewicz K, Gupta V, Bakst R, Posner M. Taxanes in cancer of the head and neck. Anticancer Drugs. 2014;25: 561-70. doi:10.1097/CAD.0000000000000086.
5. No authors listed. A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. Allergy Asthma Proc. 2011; 32: 79. doi:10.2500/aap.2011.32.3409.
6. Flatters SJ, Xiao WH, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett. 2006; 397: 219-223. doi:S0304-3940(05)01407-2 [pii] 10.1016/j.neulet.2005.12.013.
7. Gong LH, Chen XX, Wang H, Jiang QW, Pan SS, Qiu JG, et al. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells. Oxid Med Cell Longev. 2014;: 906804. doi:10.1155/2014/906804.
8. Jiang H, Tao W, Zhang M, Pan S, Kanwar JR, Sun X. Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Cancer Invest. 2010; 28: 74-84. doi:10.3109/07357900902744510.
9. Bocci G, Di Paolo A, Danesi R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis. 2013; 16: 481-92. doi:10.1007/s10456-013-9334-0.
10. Zhang M, Tao W, Pan S, Sun X, Jiang H. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs. 2009; 20: 355-63. doi:10.1097/CAD.0b013e3283299f36.
11. Jiang H, Tao W, Zhang M, Pan S, Kanwar JR, Sun X. Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Cancer Invest. 2010;28: 74-84. doi:10.3109/07357900902744510.
12. Maqbool R, Hussain MU. MicroRNAs and human diseases: diagnostic and therapeutic potential. Cell Tissue Res. 2014; doi:10.1007/s00441-013-1787-3.
13. Le XF, Merchant O, Bast RC, Calin GA. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron. 2010; 3: 137-47. doi:10.1007/s12307-010-0037-4.
14. Zhang X, Yu H, Lou JR, Zheng J, Zhu H, Popescu NI, et al. MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 2011; 286: 1429-35. doi:M110.146530 [pii] 10.1074/jbc.M110.146530.
15. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1236-43. doi:1055-9965.EPI-12-0173 [pii] 10.1158/1055-9965.EPI-12-0173.
16. Sandhu S, Garzon R. Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol. 2011; 38: 781-7. doi:S0093-7754(11)00215-6 [pii] 10.1053/j.seminoncol.2011.08.007.
17. Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res. 2006; 12: 4331-8. doi:12/14/4331 [pii] 10.1158/1078-0432.CCR-05-2762.
18. Kanwar JR, Palmano KP, Sun X, Kanwar RK, Gupta R, Haggarty N, et al. Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol Cell Biol. 2008; 86: 277-88. doi:7100163[pii]10.1038/sj.icb.7100163.
19. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29. doi:10.3322/caac.20138.
20. Montero AJ, Adams B, Diaz-Montero CM, Gluck S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol. 2011; 4: 329-34. doi:10.1586/ecp.11.7.
21. Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004; 64: 3994-4000. doi:10.1158/0008-5472.CAN-04-058064/11/3994 [pii].
22. Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013; 49: 3387-95. doi:S0959-8049(13)00541-8 [pii] 10.1016/j.ejca.2013.06.038.
23. Loven D, Hasnis E, Bertolini F, Shaked Y. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today. 2013; 18: 193-201. doi:S1359-6446(12)00274-7 [pii] 10.1016/j.drudis.2012.07.015.
24. Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, et al. A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer. 2010; 116: 1751-6. doi:10.1002/cncr.24902.
25. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009; 28: 369-78. doi:10.1007/s10555-009-9188-5.
26. Goga A, Benz C. Anti-oncomir suppression of tumor phenotypes. Mol Interv. 2007; 7: 199-202. doi:10.1124/mi.7.4.6.
27. Fiorucci G, Chiantore MV, Mangino G, Percario ZA, Affabris E, Romeo G. Cancer regulator microRNA: potential relevance in diagnosis, prognosis and treatment of cancer. Curr Med Chem. 2012; 19: 461-74. doi:BSP/CMC/E-Pub/2012/043 [pii].
28. Plummer PN, Freeman R, Taft RJ, Vider J, Sax M, Umer BA, et al. MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res. 2013; 73: 341-52. doi:0008-5472.CAN-12-0271 [pii] 10.1158/0008-5472.CAN-12-0271.
29. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res. 2007; 101: 59-68. doi:CIRCRESAHA.107.153916 [pii] 10.1161/CIRCRESAHA.107.153916.
30. Melton C, Judson RL, Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature. 2010; 463: 621-6. doi:nature08725 [pii] 10.1038/nature08725.
31. Worringer KA, Rand TA, Hayashi Y, Sami S, Takahashi K, Tanabe K, et al. The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell Stem Cell. 2014; 14: 40-52. doi:S1934-5909(13)00492-X [pii] 10.1016/j.stem.2013.11.001.